225 related articles for article (PubMed ID: 26412111)
1. Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
Van Eygen V; Thys K; Van Hove C; Rimsky LT; De Meyer S; Aerssens J; Picchio G; Vingerhoets J
J Med Virol; 2016 May; 88(5):798-806. PubMed ID: 26412111
[TBL] [Abstract][Full Text] [Related]
2. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Rimsky L; Vingerhoets J; Van Eygen V; Eron J; Clotet B; Hoogstoel A; Boven K; Picchio G
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):39-46. PubMed ID: 22067667
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
[TBL] [Abstract][Full Text] [Related]
4. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
[TBL] [Abstract][Full Text] [Related]
5. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
6. Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
Tambuyzer L; Thys K; Hoogstoel A; Nijs S; Tomaka F; Opsomer M; De Meyer S; Vingerhoets J
Antivir Ther; 2016; 21(4):317-27. PubMed ID: 26566161
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
[TBL] [Abstract][Full Text] [Related]
8. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
[TBL] [Abstract][Full Text] [Related]
9. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
[TBL] [Abstract][Full Text] [Related]
10. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
11. [Resistance profile of rilpivirine].
Imaz A; García F; di Yacovo S; Llibre JM
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
[TBL] [Abstract][Full Text] [Related]
12. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
[TBL] [Abstract][Full Text] [Related]
13. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
[TBL] [Abstract][Full Text] [Related]
14. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
Porter DP; Daeumer M; Thielen A; Chang S; Martin R; Cohen C; Miller MD; White KL
Viruses; 2015 Dec; 7(12):6360-70. PubMed ID: 26690199
[TBL] [Abstract][Full Text] [Related]
15. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
16. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY;
Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446
[TBL] [Abstract][Full Text] [Related]
17. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.
Hayashida T; Hachiya A; Ode H; Nishijima T; Tsuchiya K; Sugiura W; Takiguchi M; Oka S; Gatanaga H
J Antimicrob Chemother; 2016 Oct; 71(10):2760-6. PubMed ID: 27330069
[TBL] [Abstract][Full Text] [Related]
18. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
[TBL] [Abstract][Full Text] [Related]
19. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
20. Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
Mohamed S; Ravet S; Camus C; Khiri H; Olive D; Halfon P
J Med Virol; 2014 Mar; 86(3):394-403. PubMed ID: 24248806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
